Overview
Intra-Cellular Therapies is a biopharmaceutical company focused on CNS disorders, best known for Caplyta (lumateperone), an FDA-approved treatment for schizophrenia and bipolar depression. Their drug discovery platform targets intracellular signaling pathways in neurons.
More in Neuropharmaceuticals
Latest industry news
Synchron Pauses Brain Implant Trials After Performance Issues Surface
2026-11-12 ยท Industry
Generative AI Is Closing the Gap on Brain-Computer Interface Accuracy and Resolution
2026-11-11 ยท Research
Spiking Neural Networks Emerge as a Viable Shield Against Signal Noise in Brain-Computer Interfaces
2026-11-10 ยท Research
China's Brain-Reading Device Hits 94% Mind-Typing Accuracy Over a Full Day of Use
2026-11-09 ยท Research
Company details
Category
๐ Neuropharmaceuticals
Location
New York, USA
Funding
Public ยท NASDAQ: ITCI
Listed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ